Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia

Haematologica. 2015 Jul;100(7):e250-3. doi: 10.3324/haematol.2014.123034. Epub 2015 Mar 27.

Authors

Harinder Gill¹, Cheuk-Him Man¹, Alvin H W Ip², William W L Choi², Howard C H Chow¹, Yok-Lam Kwong¹, Anskar Y H Leung³

Affiliations

¹ Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China.
² Department of Pathology, the University of Hong Kong, China.
³ Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China ayhleung@hku.hk.

No abstract available

Keywords: FLT3-ITD; Sorafenib; acute myeloid leukemia; azacitidine.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects
Azacitidine / therapeutic use*
Cell Line, Tumor
Drug Administration Schedule
Drug Synergism
Gene Expression
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Mice
Monocytes / drug effects
Monocytes / immunology
Monocytes / pathology
Mutation
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Remission Induction
Sorafenib
Survival Analysis
Treatment Outcome
Xenograft Model Antitumor Assays
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
fms-Like Tyrosine Kinase 3 / genetics
fms-Like Tyrosine Kinase 3 / immunology

Substances

Antineoplastic Agents
Phenylurea Compounds
Protein Kinase Inhibitors
Niacinamide
Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3
Azacitidine